- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.11. | APOE4 and CRISPR are reframing Alzheimer's Risk | ||
| 21.11. | Eli Lilly becomes first drugmaker to hit $1 trillion in market value | ||
| 21.11. | GSK, Anaptysbio sue each other over Jemperli revenue | ||
| 21.11. | FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M | ||
| 21.11. | A brain biotech's top drug fails against MS | ||
| 20.11. | Moderna secures $1.5B lifeline as it looks to break even in 2028 | ||
| 20.11. | Aspen raises $115M for a Parkinson's stem cell treatment | ||
| 20.11. | Abbott to acquire Exact Sciences for about $21B | ||
| 20.11. | With new approvals, Regeneron's higher-dose Eylea gets more competitive | ||
| 19.11. | Agios shares fall on mixed sickle cell results for blood disease drug | ||
| 19.11. | UnitedHealth adds former FDA commissioner Scott Gottlieb to board | ||
| 19.11. | Alkermes escalates bidding war; US biotech risks 'falling behind' China | ||
| 18.11. | RNAi biotech Arrowhead wins first FDA approval | ||
| 18.11. | Roche pill notches win in early breast cancer | ||
| 18.11. | Merck's blockbuster-to-be cardiovascular drug scores in another heart study | ||
| 18.11. | Zymeworks to change course, pursue 'royalty-driven' biotech model | ||
| 17.11. | J&J adds to pharma's M&A spree with $3B buyout of startup Halda | ||
| 17.11. | FDA limits Elevidys use; Nxera to lay off staff | ||
| 17.11. | A 'DNA damage repair' drugmaker raises $115M for cancer treatments | ||
| 17.11. | Solve lines up $120M to push ADCs into further testing | ||
| 17.11. | The inspection-ready operating model for clinical trials | ||
| 17.11. | Securing quality in every dose: 5 essential capabilities for CGT developers to look for in a fill-finish CDMO | ||
| 17.11. | Sofinnova Partners raises another $750M to back biotech, medtech startups | ||
| 14.11. | To Wall Street, a new bidding war puts Alkermes in a tough spot | ||
| 14.11. | Bristol Myers, J&J's new blood thinner fails first big test |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .